The purpose of this study is to evaluate the efficacy of 2 doses of ITI-1284 (10 mg and 20 mg) administered once daily as an adjunctive therapy with a current antidepressant treatment or buspirone compared with placebo in patients with Generalized Anxiety Disorder.
CONTACT US ABOUT ANXIETY TRIALAnxiety Study
Description
Eligibility Criteria
Male or female between the ages of 18 and 65 years old; Meets criteria for moderate or severe Generalized Anxiety Disorder; Currently having an inadequate response to paroxetine, venlafaxine XR, duloxetine, escitalopram, or buspirone; Has a body mass index (BMI) of 19-40kg
Duration
10 Week Study
Intervention
Daily dose of ITI-128 10mg/20mg or placebo by mouth.